<SEC-DOCUMENT>0001193125-21-298277.txt : 20211014
<SEC-HEADER>0001193125-21-298277.hdr.sgml : 20211014
<ACCEPTANCE-DATETIME>20211014071542
ACCESSION NUMBER:		0001193125-21-298277
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211014
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211014
DATE AS OF CHANGE:		20211014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRISPR Therapeutics AG
		CENTRAL INDEX KEY:			0001674416
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473173478
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37923
		FILM NUMBER:		211322480

	BUSINESS ADDRESS:	
		STREET 1:		BAARERSTRASSE 14
		CITY:			ZUG
		STATE:			V8
		ZIP:			CH-6300
		BUSINESS PHONE:		6173154600

	MAIL ADDRESS:	
		STREET 1:		BAARERSTRASSE 14
		CITY:			ZUG
		STATE:			V8
		ZIP:			CH-6300
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d212374d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crsp="http://www.crisprtx.com/20211014" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-10-14_to_2021-10-14">00-0000000</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-10-14_to_2021-10-14">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-10-14_to_2021-10-14">0001674416</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="crsp-20211014.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-10-14_to_2021-10-14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001674416</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-14</xbrli:startDate> <xbrli:endDate>2021-10-14</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-10-14_to_2021-10-14">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt:datemonthdayyearen">October 14, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-10-14_to_2021-10-14">CRISPR THERAPEUTICS AG</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:edgarprovcountryen">Switzerland</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-10-14_to_2021-10-14">001-37923</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not Applicable</span> </span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-10-14_to_2021-10-14">Baarerstrasse 14</ix:nonNumeric><br /><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-10-14_to_2021-10-14">6300</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-10-14_to_2021-10-14">Zug</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:countrynameen">Switzerland</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold">Not Applicable</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: +<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-10-14_to_2021-10-14">41 (0)41</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-10-14_to_2021-10-14">561 32 77</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-10-14_to_2021-10-14">Common Shares, CHF 0.03 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-10-14_to_2021-10-14">CRSP</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-10-14_to_2021-10-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(a) Appointment of New Chief Financial Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Appointment of Brendan Smith as Senior Vice President and Chief Financial Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2021, CRISPR Therapeutics AG (the &#8220;Company&#8221;) announced the hiring and appointment of Brendan Smith as its Senior Vice President and Chief Financial Officer, effective immediately. Mr.&#160;Smith will also serve as the Company&#8217;s principal financial officer and principal accounting officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to joining the Company, Mr.&#160;Smith, aged 46, served as Chief Financial Officer and Corporate Strategy of Translate Bio, Inc., or Translate Bio, from April 2021 to September 2021. Translate Bio is a publicly-traded company where he oversaw accounting, procurement, financial planning and analysis, investor relations, IT and corporate strategy functions. Mr.&#160;Smith previously held various roles at Boston Consulting Group, or BCG, a management consulting firm, serving most recently as a partner and associate director from July 2018 to March 2021, and as principal healthcare expert from September 2016 to June 2018. At BCG, Mr.&#160;Smith led integrated biopharmaceutical client engagements that included planning and executing on research and development strategy, operations, business development and deal diligence. Mr.&#160;Smith served as vice president, head of business operations for worldwide research and development at Pfizer Inc., or Pfizer, a pharmaceutical company, from September 2014 to September 2016 and as executive director, head of business strategy and operations at Pfizer from November 2012 to September 2014, where he led financial and headcount planning across discovery and development operations. Mr.&#160;Smith received a B.S. in biochemistry from Worcester Polytechnic Institute and an M.B.A. from Harvard Business School. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Mr.&#160;Smith </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Mr.&#160;Smith&#8217;s appointment to the position of Senior Vice President and Chief Financial Officer, the Company&#8217;s wholly owned subsidiary, CRISPR Therapeutics, Inc (&#8220;CRISPR Inc.&#8221;), entered into a Employment Agreement (the &#8220;Employment Agreement&#8221;) with Mr.&#160;Smith dated October&#160;14, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Employment Agreement, Mr.&#160;Smith will receive an annual salary of $435,000 and he will be eligible to participate in the Company&#8217;s annual bonus program, with a target bonus of 40% of his base salary. Mr.&#160;Smith&#8217;s bonus for 2021 will be <span style="white-space:nowrap">pro-rated</span> to reflect his start date with the Company. Mr.&#160;Smith will also be eligible to participate in the Company&#8217;s 2018 Stock Option and Incentive Plan, and will receive (i)&#160;an inaugural, <span style="white-space:nowrap">one-time</span> grant of options to purchase 90,000 of the Company&#8217;s common shares (the &#8220;Option Award&#8221;) and (ii)&#160;an inaugural, <span style="white-space:nowrap">one-time</span> grant of 15,000 restricted stock units corresponding to an equivalent number of the Company&#8217;s common shares (the &#8220;RSU Award&#8221;). Twenty-five percent of the Option Award will vest on October&#160;14, 2022, and the remaining seventy-five percent of the Option Award will vest ratably on a monthly basis over the following three years. Twenty-five percent of the RSU Award will vest on first, second, third and fourth anniversary of the grant date of such award, subject, in each case, to Mr.&#160;Smith&#8217;s continued employment with CRISPR Inc., the Company or any other subsidiary of the Company. Mr.&#160;Smith will also receive a <span style="white-space:nowrap">one-time</span> payment of $75,000, which is subject to forfeiture in the event Mr.&#160;Smith&#8217;s employment with the Company is terminated for any reason prior to November&#160;14, 2022. Mr.&#160;Smith will be eligible to participate in the Company&#8217;s 401(k) plan, health plans and other benefits on the same terms as all other Company employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Employment Agreement, in the event we terminate his employment without Cause, or Mr.&#160;Smith resigns for Good Reason (both as defined in the Employment Agreement), the terminating party will be required to give six months&#8217; notice (the &#8220;Notice Period&#8221;). During the Notice Period, Mr.&#160;Smith shall continue to be entitled to all compensation under the Employment Agreement, and all stock options and stock based awards shall continue to vest from the date notice of termination is given until the last day of the Notice Period. In addition, Mr.&#160;Smith will be entitled to receive a <span style="white-space:nowrap">pro-rated</span> bonus for the duration of the Notice Period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No later than fifteen days following the delivery of notice by us to Mr.&#160;Smith of a termination without Cause or the delivery of a notice of resignation by Mr.&#160;Smith for Good Reason, Mr.&#160;Smith will be placed on &#8220;administrative leave.&#8221; During this period of administrative leave, Mr.&#160;Smith may enter into consulting arrangements and accept board positions with other companies and will be allowed to engage in other employment, so long as that employment doesn&#8217;t interfere with his obligations under the Employment Agreement. However, Mr.&#160;Smith will continue to be entitled to all compensation under the Employment Agreement through the administrative leave period, which terminates at the end of the Notice Period. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Mr.&#160;Smith&#8217;s employment is terminated by us without Cause or by Mr.&#160;Smith for Good Reason, in each case, within 12 months following a Change in Control (as defined in the Employment Agreement), the Notice Period will become 12 months and all equity awards held by Mr.&#160;Smith on such date that the notice of termination or resignation is delivered will vest, or similar other restrictions will expire, and such awards become exercisable or nonforfeitable, subject to his execution of a release of any claims in favor of us. However, in the event we determine at the time of the Change in Control, based upon an opinion of counsel, that the acceleration described in the preceding sentence is not permissible under applicable law, all stock options and stock-based awards held by Mr.&#160;Smith as of the date of the Change in Control, shall vest and become exercisable or nonforfeitable as of the date of the Change in Control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no transactions between Mr.&#160;Smith and the Company subject to disclosure pursuant to Item 404(a) of Regulation <span style="white-space:nowrap">S-K,</span> and there is no arrangement or understanding between Mr.&#160;Smith and any other persons or entities pursuant to which Mr.&#160;Smith was appointed as officer of the Company. There are no family relationships between Mr.&#160;Smith and any of our directors or executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the material terms of Mr.&#160;Smith&#8217;s employment arrangement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Employment Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full text of the press release announcing Mr.&#160;Smith&#8217;s appointment is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(b) Retirement of Chief Financial Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2021, Michael Tomsicek retired from his position as Senior Vice President and Chief Financial Officer of the Company. Mr.&#160;Tomsicek&#8217;s decision to retire is not the result of any disagreement regarding the Company&#8217;s financial reporting or accounting policies, procedures, estimates, or judgments. Mr.&#160;Tomsicek is expected to remain employed as an employee of CRISPR Therapeutics, Inc. until a date on or before December&#160;31, 2021, during which time Mr.&#160;Tomsicek&#8217;s outstanding options to purchase common shares of the Company that are not vested will continue to vest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Exhibits</span>. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d212374dex101.htm">Employment Agreement, dated October&#160;14, 2021, by and between CRISPR Therapeutics, Inc. and Brendan Smith. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d212374dex991.htm">Press Release by CRISPR Therapeutics AG, dated October&#160;14, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from this Current Report on Form <span style="white-space:nowrap">8-K,</span> formatted in Inline XBRL.</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">CRISPR THERAPEUTICS AG</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: October&#160;14, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Samarth Kulkarni</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Samarth Kulkarni, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d212374dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;<U>Agreement</U>&#148;) is made as of the 14th day of October, 2021 between CRISPR Therapeutics, Inc., a
Delaware corporation<B><I> </I></B>(the &#147;<U>Company</U>&#148;), and Brendan Smith (the &#147;<U>Executive</U>&#148; and, together with the Company, the &#147;<U>Parties</U>&#148; or each individually, a &#147;<U>Party</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Employment Agreement shall become effective upon the later of the (i)&nbsp;full execution by both Parties; or (ii)&nbsp;ten (10)
business days after the Company provided Executive with notice of this Agreement and the Exhibits (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company is a wholly owned subsidiary of CRISPR Therapeutics AG (&#147;<U>Parent</U>&#148; or &#147;<U>CRISPR AG</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent and the Company are each subject to the Swiss Ordinance act against excessive compensation in listed companies as a result of
the of listing of the common shares of Parent on the NASDAQ Global Market; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Executive are parties to that
certain offer letter dated on or about October&nbsp;12, 2021 (the &#147;<U>Prior Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in
consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Position and
Duties</U>. The employment of the Executive by the Company will commence on the date hereof. The Executive will serve as the Senior Vice President, Chief Financial Officer of the Company. The Executive shall have responsibilities and duties
consistent with such position and such other responsibilities and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the &#147;<U>CEO</U>&#148;) which are not inconsistent with the Executive&#146;s skills
and experience or his ability to discharge his responsibilities in the positions noted above. The Executive shall devote the Executive&#146;s full working time and efforts to the business and affairs of the Company except as otherwise permitted
under Section&nbsp;3(b)(i). Notwithstanding the foregoing, the Executive may engage in charitable or other community activities, as long as such services and activities are disclosed to the Board of Directors of Parent (the &#147;<U>Board</U>&#148;)
and do not materially interfere with the Executive&#146;s performance of the Executive&#146;s duties to the Company as provided in this Agreement. During the period which the Executive is employed pursuant to this Agreement (the &#147;<U>Employment
Period</U>&#148;), the Executive&#146;s principal place of employment will be in the Greater Boston, Massachusetts area; however, the Company may require the Executive to travel temporarily to other locations in connection with the Company&#146;s
business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation and Related Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. During the Employment Period, the Company shall pay the Executive, as compensation for the
performance of the Executive&#146;s duties and obligations under this Agreement, an annual base salary of $435,000, payable in a manner that is consistent with the Company&#146;s usual payroll practices for senior executives. The Executive&#146;s
base salary shall be reviewed annually by each of the Compensation Committee of the Board or any successor to such committee (the &#147;<U>Committee</U>&#148;) and the Board or for adjustment. Such adjustment, if any, shall be within the sole
discretion of the Board. The annual base salary in effect at any given time is referred to herein as &#147;Base Salary.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Bonus</U>. During the Employment Period, the Executive shall be eligible to receive an annual target
bonus (a &#147;<U>Bonus</U>&#148;) if, as reasonably determined by the Board or, to the extent delegated by the Board, the Committee one or more of the performance targets annually determined by the Board or the Committee (&#147;<U>Performance
Targets</U>&#148;) is achieved. If all of the Performance Targets are achieved, the Bonus will equal not less than 40&nbsp;percent of the Executive&#146;s Base Salary (the &#147;<U>Target Bonus</U>&#148;). In the event that less than all of the
Performance Targets are met by Executive, the Bonus paid in respect of this paragraph may be less than the Target Bonus. Except as set forth in Section&nbsp;5(a) hereof, the Executive must be employed by the Company on the day any such earned Bonus
is paid which shall be not later than 2<SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">2</SUB> months after the end of each calendar year. The Executive&#146;s target bonus opportunity as a percentage of Base Salary
may be reviewed periodically and adjusted in the sole discretion of the Board. After any such adjustment, the term &#147;Target Bonus&#148; shall refer to the increased amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity Compensation</U>. The Executive shall be eligible to participate in Parent&#146;s equity incentive plan
according to its terms and conditions, as defined by Parent from time to time in its sole discretion. Both entitlement to any equity awards and the amount shall be determined by Parent in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. During the Employment Period, the Executive shall be entitled to receive reimbursement for all
reasonable expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Benefits</U>. During the Employment Period, the Executive shall be entitled to participate in or receive
benefits under any employee benefit plan or arrangement currently maintained or which may, in the future, be made available by the Company generally to its executives and key management employees, subject to and on a basis consistent with the terms,
conditions and overall administration of such plan or arrangement. Any payments or benefits payable to the Executive under a plan or arrangement referred to in this Section&nbsp;2(e) in respect of any calendar year during which the Executive is
employed by the Company for less than the whole of such year shall, unless otherwise provided in the applicable plan or arrangement, be prorated in accordance with the number of days in such calendar year during which the Executive is so employed.
Should any such payments or benefits accrue on a fiscal (rather than calendar) year, then the proration in the preceding sentence shall be on the basis of a fiscal year rather than calendar year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacations</U>. The Executive shall be entitled to accrue up to
20 paid vacation days in each year, which shall be accrued ratably. In other respects, the Company&#146;s vacation policy as the same may then be in effect shall apply to vacations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Approval by Shareholders&#146; Meeting and Mandatory Law</U>. Any compensation (including bonus, equity awards
and fringe benefits) to be paid under this Agreement, is, to the extent required by Swiss laws and the Parent&#146;s Article of Association, subject to approval by the general meeting of shareholders&#146; of Parent. In the event of a conflict
between this Agreement and applicable mandatory Swiss law, the Company shall have the right to unilaterally modify the Agreement to the extent necessary to comply with mandatory law with immediate effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Lost Opportunity Compensation</U>. To offset losses the Executive incurred in connection with the transitioning
of his employment to the Company, the Company will make a <FONT STYLE="white-space:nowrap">one-time</FONT> payment to the Executive in the amount of $75,000 in the first payroll following 30 days of employment with the Company (usually within the
first 60 days of employment). This payment is subject to the usual required withholdings.&nbsp;The Executive understands and agrees that, in the event his employment with the Company is terminated for any reason prior to November&nbsp;14, 2022, he
will reimburse&nbsp;the Company, within one (1)&nbsp;month after such employment termination, for this full amount ($75,000). The Executive further agrees that amount may be collected by the Company, either directly or indirectly, from
(i)&nbsp;payment of any kind due to the Executive from the Company or any affiliate thereof including, without limitation, accrued wages, vacation, final wages, and expense reimbursements to the fullest extent permitted by applicable law; and/or
(ii)&nbsp;the forfeiture or cancellation of any equity interest owned by you in CRISPR AG, the Company or any subsidiary or affiliate thereof, whether now existing or hereafter formed, and regardless of the form such equity interest (e.g., common
shares, options to acquire common shares or otherwise). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. The Executive&#146;s employment shall continue until it is terminated in accordance with this
Agreement. Upon service of a Notice of Termination (as defined below), the Executive shall resign from all offices and functions assumed in relation to this Agreement effective upon first request of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company without Cause or by Executive for Good Reason; Notice Period</U>. In the event that
the Company elects to terminate the Executive&#146;s employment without Cause (as defined below) or the Executive elects to resign from Executive&#146;s employment with Good Reason (as defined below) (in either case an &#147;<U>Involuntary
Departure</U>&#148;), the Party electing to end the employment relationship shall provide the other Party with a Notice of Termination (as defined below) of the Involuntary Departure specifying a notice period (the &#147;<U>Notice Period</U>&#148;)
of six (6)&nbsp;months, effective as per the end of a calendar month; provided that, in the case that the Notice of Termination of an Involuntary Departure is provided within the 12 month period following a Change in Control (the &#147;<U>Change in
Control Period</U>&#148; or &#147;<U>CIC Period</U>&#148;), then the Notice Period shall be 12 months. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;During the Notice Period following a Notice of Termination of an Involuntary Departure, the
Executive shall continue to be available to provide services to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the extent requested by the Company or the Board, provided at any time during the Notice Period the Company may replace the Executive&#146;s position and/or direct the Executive to perform other
or reduced work; provided further that, upon the 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following such Notice of Termination (or such earlier date as the Company shall determine in its sole discretion), the Company shall
release the Executive from his working obligations pursuant to Section&nbsp;3(b)(i) (except to the extent the parties otherwise agree) and place the Executive on administrative leave for the remainder of the Notice Period (&#147;<U>Administrative
Leave</U>&#148;). During such Administrative Leave, the Executive (A)&nbsp;may enter into consulting arrangements and accept board positions provided such outside business activities do not interfere with Executive&#146;s obligations under this
Agreement including without limitation, pursuant to Section&nbsp;7 and (B)&nbsp;shall be free to engage in other employment provided that such employment does not interfere with Executive&#146;s obligations under this Agreement including without
limitation, pursuant to Section&nbsp;7. The Company shall be prohibited during the Administrative Leave from reducing any compensation to which the Executive is entitled to receive during the remainder of the Notice Period pursuant to
Section&nbsp;3(b)(ii). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;With respect to compensation during the Notice Period following a
Notice of Termination of an Involuntary Departure, and subject to (i)&nbsp;the Executive signing, within 30 days following the date that the Notice of Termination is given, a Release of Claims in a form reasonably required by the Company containing,
among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> a reaffirmation of all of the
Executive&#146;s Continuing Obligations and, in the Company&#146;s sole discretion, a <FONT STYLE="white-space:nowrap">one-year</FONT> post-employment noncompetition agreement, and shall provide that if the Executive breaches any of the
Executive&#146;s Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#147;<U>Release</U>&#148;) and (ii)&nbsp;Section&nbsp;6, the Executive: (A)&nbsp;shall continue to receive the Base Salary and employee
benefits consistent with the Company&#146;s then existing benefits plans and programs; (B)&nbsp;shall be entitled to receive an amount equal to the Target Bonus with respect to the Notice Period (i.e., a prorated Target Bonus based upon the number
of days in the applicable Notice Period), which amount shall be payable no more than 60 days after the Notice of Termination (provided that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second
calendar year, such Target Bonus shall be paid in the second calendar year); (C) shall continue to vest through the last day of the Notice Period in any [time based] equity awards outstanding as of the date the Notice of Termination is given;
provided, and notwithstanding the foregoing, Section&nbsp;5(a) may apply if the Notice of Termination of an Involuntary Departure occurs during a CIC Period, and (D)&nbsp;shall not continue to accrue vacation under Section&nbsp;2(f). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If during the Notice Period following a Notice of Termination of an Involuntary Departure, the
Company terminates the Executive&#146;s employment for Cause, then the Company shall provide a restated Notice of Termination and the Notice Period shall end on the earlier date set forth in the restated Notice of Termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Death</U>. The Executive&#146;s employment hereunder shall terminate upon his death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability</U>. The Company may terminate the Executive&#146;s
employment if the Executive is disabled and unable to perform the essential functions of the Executive&#146;s then existing position or positions with or without reasonable accommodation for a period of 180&nbsp;days (which need not be consecutive)
in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s then existing
position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or
the Executive&#146;s guardian shall have no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the
issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of such
issue shall be binding on the Executive. Nothing in this Section&nbsp;3(d) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29&nbsp;U.S.C.
&#167;2601 <I>et</I><I></I><I>&nbsp;seq</I>. and the Americans with Disabilities Act, 42&nbsp;U.S.C. &#167;12101 <I>et</I><I></I><I>&nbsp;seq.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for
Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Executive Without Good Reason</U>. The Executive may terminate his employment
hereunder at any time without Good Reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cause</U>. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean: (i)&nbsp;the
Executive&#146;s commission of any felony or commission of any crime involving fraud, dishonesty or moral turpitude; (ii)&nbsp;the Executive&#146;s commission or attempted commission of or participation in a fraud or act of dishonesty against the
Company; (iii)&nbsp;the Executive&#146;s material breach of any contract or agreement between the Executive and the Company or the Executive&#146;s material breach of any legal duty he owes to the Company; (iv)&nbsp;conduct by the Executive that
constitutes insubordination, incompetence or neglect of duties; (v)&nbsp;the Executive&#146;s failure to perform the duties, functions and responsibilities of the Executive&#146;s position; or (vi)&nbsp;the Executive&#146;s failure to cooperate with
a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be
relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation; provided, however, the actions or conduct described in clauses (iv)&nbsp;and
(v)&nbsp;above shall only constitute Cause if the Company provides the Executive with written notice thereof and the Executive has not, within 30 days of receipt such written notice, discontinued the cited conduct or remedied the failure to perform
and further provided that lawful actions taken by the Executive in the exercise of his rights under the United States Constitution shall not constitute a breach of subsection (vi)&nbsp;above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Good Reason</U>. For purposes of this
Agreement, &#147;<U>Good Reason</U>&#148; shall mean that the Executive has complied with the &#147;<U>Good Reason Process</U>&#148; (hereinafter defined) following the occurrence of any of the following events: (i)&nbsp;a material diminution in the
Executive&#146;s responsibilities, authority and function, an adverse change to Executive&#146;s job title, or a change in Executive&#146;s reporting relationship that results in the Executive no longer reporting directly to the CEO; (ii)&nbsp;a
material reduction in Base Salary except pursuant to a salary reduction program affecting substantially all of the employees of the Company, provided that it does not adversely affect the Executive to a greater extent than other similarly situated
employees; (iii)&nbsp;a material change in the principal geographic location at which the Executive provides services to the Company outside of the Greater Boston, Massachusetts area; or (iv)&nbsp;the material breach of this Agreement by the Company
(each a &#147;<U>Good Reason Condition</U>&#148;). Good Reason Process shall mean that (i)&nbsp;the Executive reasonably determines in good faith that a Good Reason Condition has occurred; (ii)&nbsp;the Executive notifies the Company in writing of
the first occurrence of the Good Reason Condition within 60 days of the occurrence of such condition; (iii)&nbsp;the Executive cooperates in good faith with the Company&#146;s efforts, for a period not less than 30&nbsp;days following such notice
(the &#147;<U>Cure Period</U>&#148;), to remedy the Good Reason Condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;the Executive terminates employment within 60&nbsp;days after the end of
the Cure Period. If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(c), any
termination of the Executive&#146;s employment by either the Company or the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;<U>Notice of Termination</U>&#148; shall
mean a notice which shall indicate the specific termination provision in this Agreement relied upon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Date of Termination</U>. For purposes of this Agreement, &#147;Date of Termination&#148; shall
mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(d) or by the Company for Cause under
Section&nbsp;3(e), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment terminates as a result of an Involuntary Departure under Section&nbsp;3(b), the last day of the Notice Period; (iv)&nbsp;if the
Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(f) without Good Reason, 30&nbsp;days after the date on which a Notice of Termination is given (unless the Company waives all or part of the thirty (30)&nbsp;day period).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation Upon Termination</U>. If the Executive&#146;s employment with the Company is terminated for any
reason, the Company shall pay or provide to the Executive (or to the Executive&#146;s authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in
accordance with Section&nbsp;2(d) of this Agreement); (iii) subject to Section&nbsp;3(b)(ii)(D), unused vacation that accrued through the Date of Termination; and (iv)&nbsp;any vested benefits the Executive may have under any employee benefit plan
of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (together, the &#147;<U>Accrued Benefit</U>&#148;) on or before the time required by law
but in no event more than 30 days after the Executive&#146;s Date of Termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Change in Control</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceleration of Vesting</U>. In the event a Notice of Termination of an Involuntary Termination occurs during the
CIC Period, and subject to the Executive signing, within 60 days following the Notice of Termination, a Release and the Release becoming effective and <FONT STYLE="white-space:nowrap">non-revocable</FONT> within such
<FONT STYLE="white-space:nowrap">60-day</FONT> period, all time based stock options and time based stock-based awards held by the Executive as of the date of the Notice of Termination, shall vest and become exercisable or nonforfeitable.
Notwithstanding the foregoing, if, at the time of a Change in Control, the Company determines in its sole discretion, in reliance upon an opinion of counsel in form and substance satisfactory to the Company, that the acceleration in the prior
sentence would not be permissible under applicable law, then in lieu of the acceleration in the prior sentence, all time based stock options and time based stock-based awards held by the Executive as of the date of such Change in Control, shall vest
and become exercisable or nonforfeitable as of the date of such Change in Control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Excise Tax</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that any compensation,
payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (the &#147;<U>Parachute Payments</U>&#148;), would be subject
to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Excise Tax</U>&#148;), the following provisions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;If the Parachute Payments, reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of
the Federal, state, and local income and employment taxes payable by the Executive on the amount of the Parachute Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the Executive shall be
entitled to the full benefits payable under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;If the Threshold Amount is less
than (x)&nbsp;the Parachute Payments, but greater than (y)&nbsp;the Parachute Payments reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of the Federal, state, and local income and employment taxes on the amount of the Parachute
Payments which are in excess of the Threshold Amount, then the Parachute Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Parachute Payments shall not exceed the Threshold Amount. In such event, the
Parachute Payments shall be reduced in the following order: (1)&nbsp;cash payments not subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT
STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits. To the extent any payment is to be made over time (<I>e.g.</I>, in installments, etc.), then the payments shall be reduced in reverse chronological order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this Section&nbsp;5(c),
&#147;Threshold Amount&#148; shall mean three times the Executive&#146;s &#147;base amount&#148; within the meaning of Section&nbsp;280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and &#147;Excise Tax&#148;
shall mean the excise tax imposed by Section&nbsp;4999 of the Code, and any interest or penalties incurred by the Executive with respect to such excise tax. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) All calculations and determinations under Sections 5(c)(i) and 5(c)(ii) shall be made by an independent accounting firm
or independent tax counsel appointed by the Company (the<B></B><B>&nbsp;&#147;</B><U>Tax Counsel</U><B>&#148;</B>) whose determinations shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the
calculations and determinations required by Sections 5(c)(i) and 5(c)(ii), the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the application of Section&nbsp;280G and Section&nbsp;4999 of the Code. The
Company and the Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request in order to make its determinations under Sections 5(c)(i) and 5(c)(ii). The Company shall bear all costs the Tax
Counsel may reasonably incur in connection with its services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this
Section&nbsp;5, &#147;Change in Control&#148; shall mean any of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any
&#147;person,&#148; as such term is used in Sections&nbsp;13(d) and&nbsp;14(d) of the Securities Exchange Act of 1934, as amended (the &#147;<U>Act</U>&#148;) (other than Parent, any of its subsidiaries, or any trustee, fiduciary or other person or
entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with all &#147;affiliates&#148; and &#147;associates&#148; (as such terms are defined in
<FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Act) of such person, shall become the &#147;beneficial owner&#148; (as such term is defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> under the Act), directly or
indirectly, of securities of Parent representing 50&nbsp;percent or more of the combined voting power of the Company&#146;s then outstanding securities having the right to vote in an election of the Board (&#147;<U>Voting Securities</U>&#148;) (in
such case other than as a result of an acquisition of securities directly from Parent); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the
date a majority of the members of the Board is replaced during any <FONT STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the
appointment or election; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A)&nbsp;any consolidation or merger of
Parent where the stockholders of Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT>
under the Act), directly or indirectly, shares representing in the aggregate more than 50&nbsp;percent of the voting shares of the company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or
(B)&nbsp;any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change in Control&#148; shall not be deemed to have
occurred for purposes of the foregoing clause (i)&nbsp;solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities
beneficially owned by any person to 50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial
owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent) and immediately thereafter beneficially owns
50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities, then a &#147;Change in Control&#148; shall be deemed to have occurred for purposes of the foregoing clause&nbsp;(i). For the avoidance of doubt, a
migratory merger of Parent for the principal purpose of redomiciling Parent shall not constitute a Change in Control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Section 409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from
service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement on account of the Executive&#146;s separation from service would be considered deferred compensation subject to the 20&nbsp;percent additional tax imposed pursuant to Section&nbsp;409A(a)
of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after the
Executive&#146;s separation from service, or (B)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT>
payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the installments shall be payable in accordance with their
original schedule. Solely for purposes of Section&nbsp;409A of the Code, each installment payment under this Agreement is considered a separate payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses eligible for reimbursement under
this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be
paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses incurred in one taxable year shall not
affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not
subject to liquidation or exchange for another benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in
this Agreement constitutes <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination
of employment, then such payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the
presumptions set forth in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this Agreement will be administered in
accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder
comply with Section&nbsp;409A of the Code. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and
regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any other person if
any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Information, Noncompetition and Cooperation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality and Assignment Agreement.</U> The Executive has entered into the Proprietary Information and
Inventions Agreement (the &#147;<U>Confidentiality and Assignment Agreement</U>&#148;), attached hereto as <U>Exhibit A</U>, the terms of which are incorporated by reference as material terms of this Agreement. For purposes of this Agreement, the
obligations in this Section&nbsp;7 and those that arise in the Confidentiality and Assignment Agreement, and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to
as the &#147;Continuing Obligations.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U><B><U>.</U></B><B> </B>In order to protect the
Company&#146;s proprietary information and good will, during the Executive&#146;s employment with the Company and for a period of twelve (12)&nbsp;months following the (i)&nbsp;the delivery of a Notice of Termination, in the case of an Involuntary
Departure or (ii)&nbsp;the termination of the Executive&#146;s employment for any other reason (the &#147;<U>Restricted Period</U>,) the Executive will not, directly or indirectly, in any manner, other than for the benefit of the Company
(i)&nbsp;divert or take away customers of the Company or any of its suppliers; and/or (ii)&nbsp;solicit, entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason (other than the termination of
subordinate employees undertaken in the course of the Executive&#146;s employment with the Company). The Executive acknowledges and agrees that if the Executive violates any of the provisions of this paragraph&nbsp;7(b), the running of the
Restricted Period will be extended by the time during which the Executive engages in such violation(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Noncompetition</U>. The Executive acknowledges and agrees that in consideration and as a condition of the
Executive&#146;s promotion by the Company and in exchange for, among other things, the benefits contained in this Agreement, including without limitation the opportunity to receive enhanced post-employment severance benefits, which the Executive
acknowledges and agrees is fair and reasonable consideration that is independent from the continuation of the Executive&#146;s employment, during the Restricted Period the Executive will not directly or indirectly, whether as owner, partner,
shareholder, director, manager, consultant, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent, employee, <FONT STYLE="white-space:nowrap">co-venturer</FONT> or otherwise, engage, participate or invest in any Competing Business anywhere in the world. For purposes hereof, the term
&#147;<U>Competing Business</U>&#148; shall mean any entity engaged in the discovery, development or commercialization of gene editing technology for human therapeutics. Notwithstanding the foregoing, nothing contained hereinabove or hereinbelow
shall be deemed to prohibit the Executive from (i)&nbsp;acquiring, solely as an investment, shares of capital stock (or other interests) of any corporation (or other entity) not exceeding 2% of such corporation&#146;s (or other entity&#146;s) then
outstanding shares of capital stock (or equity interest), or (ii)&nbsp;working for a line of business, division or unit of a larger entity that competes with the Company as long as the Executive&#146;s activities for such line of business, division
or unit do not involve work by the Executive on matters that are directly competitive with the Company&#146;s business. Notwithstanding the foregoing, this Section&nbsp;7(c) shall not be enforceable during the post-employment portion of the
Restricted Period if the Executive is terminated by the Company without Cause, is laid off from employment or if the Company elects to waive the restrictions set forth in this Section&nbsp;7(c). If Section&nbsp;7(c) is enforced during the
post-employment portion of the Restricted Period, the Company shall pay the Executive at the rate of 50% of the highest annualized base salary paid to the Executive within the two year period preceding the last day of Executive&#146;s employment
(the &#147;Garden Leave Pay&#148;) during the post-employment portion of the Restricted Period. During the Restricted Period Executive will promptly (and immediately upon request) notify the Company of any change in address and each subsequent
employer or business activity including the name and address of employer or other post-Company plans and the nature of Executive&#146;s activities. The Company&#146;s election not to provide post-employment Garden Leave Pay shall be deemed a waiver
of Executive&#146;s post-employment noncompetition obligations under this Section&nbsp;7(c). In no event will Garden Leave Pay be duplicative of other pay and the Executive agrees that any Garden Leave Pay received pursuant to this Section&nbsp;7(c)
shall reduce (and shall not be in addition to) any other pay that the Executive may be entitled to receive during the post-employment portion of the Restricted Period. The Executive acknowledges that he has been advised by the Company that he has
the right to consult with counsel regarding the noncompetition restrictions contained in this Section&nbsp;7(c) prior to executing this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation and Regulatory Cooperation</U>. During and after the Executive&#146;s employment, the Executive shall
use reasonable efforts to cooperate with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that
transpired while the Executive was employed by the Company. The Executive&#146;s cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and
to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive shall use reasonable efforts to cooperate with the Company in connection with any investigation or review of
any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;7(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Injunction</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company
that might result from any breach by the Executive of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promises set forth in this Section&nbsp;7 and the Confidentiality and Assignment Agreement, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly,
subject to Section&nbsp;8 of this Agreement, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Agreement and the Confidentiality and Assignment Agreement, the Company shall be entitled, in addition to
all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Protected Reporting; Defend Trade Secrets Act Immunity</U>. Nothing in this Agreement or the Confidentiality and
Assignment Agreement, and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or communication from the Company limits the Executive&#146;s ability to file a charge or complaint
with any government agency concerning any acts or omissions that the Executive may believe constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable
federal or state law regulation or affects the Executive&#146;s ability to communicate with any government agency or otherwise participate in any investigation or proceeding that may be conducted by a government agency, including by providing
documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state
trade secret law for the disclosure of a trade secret that (i)&nbsp;is made (A)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B)&nbsp;solely for the purpose of reporting
or investigating a suspected violation of law; or (ii)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration of Disputes</U>. Any controversy or claim arising out of or relating to this Agreement or the breach
thereof or otherwise arising out of the Executive&#146;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest
extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (&#147;<U>AAA</U>&#148;) in Boston, Massachusetts
in accordance with the Employment Arbitration Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. In the event that any person or entity other than the Executive or the Company may be
a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity&#146;s agreement. Judgment upon the award rendered by the arbitrator may be entered in any court
having jurisdiction thereof. This Section&nbsp;8 shall be specifically enforceable. Notwithstanding the foregoing, this Section&nbsp;8 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary
restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction</U>. To the extent that any court action is permitted consistent with or to enforce
Section&nbsp;8 of this Agreement, the parties hereby agree that the Middlesex County Superior Court of The Commonwealth of Massachusetts shall have exclusive jurisdiction of such dispute, provided that the Company and the Executive agree that all
civil actions related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Section&nbsp;7(c) of this Agreement shall be brought in the country of Suffolk and that the superior court or the business litigation session of the superior court shall have exclusive
jurisdiction. Accordingly, with respect to any such court action, the Executive submits to the personal jurisdiction of such courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. This Agreement and the Confidentiality and Assignment Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, including the Prior Agreement, between the Parties concerning such subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>. All payments made by the Company to the Executive under this Agreement shall be net of any tax
or other amounts required to be withheld by the Company under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successor to the
Executive</U>. This Agreement shall inure to the benefit of and be enforceable by the Executive&#146;s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive&#146;s death after
her termination of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to her
death (or to her estate, if the Executive fails to make such designation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability</U>. If any
portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of
this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid
and enforceable to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The provisions of this Agreement and
the Confidentiality and Assignment Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. Except as otherwise provided in Section&nbsp;7(c), no waiver of any provision hereof shall be
effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any
subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notices, requests, demands and other communications provided for by this Agreement shall be
sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed
in writing with the Company or, in the case of the Company, at its main offices, attention of the CEO and a copy of such notice shall be sent to Crispr AG, Attention: General Counsel, at the main offices of Crispr AG. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Agreement may be amended or modified only
by a written instrument signed by the Executive and by a duly authorized representative of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This is a Massachusetts contract and shall be construed under and be governed in all respects
by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it
would be interpreted and applied by the United States Court of Appeals for the First Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment and Transfer by the Company</U>. The Company will have the right to assign and/or transfer this
Agreement to its affiliates, successors and assigns. The Executive expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ the Executive may be
transferred without the necessity that this Agreement be <FONT STYLE="white-space:nowrap">re-signed</FONT> at the time of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank. Signature page follows.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CRISPR THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Samarth Kulkarni</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Samarth&nbsp;Kulkarni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brendan Smith</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Brendan Smith</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proprietary Information and Inventions Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d212374dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g212374g1013042856765.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CRISPR Therapeutics Announces Transition of Chief Financial Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZUG, Switzerland and CAMBRIDGE, Mass. &#150; October</B><B></B><B>&nbsp;14, 2021 </B>&#150;<B> </B>(GLOBE NEWSWIRE)&nbsp;&#151; CRISPR Therapeutics
(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr.&nbsp;Smith brings more than
20&nbsp;years of financial, operational and strategic leadership experience, including as CFO of Translate Bio. He succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Mr.&nbsp;Tomsicek will
remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I&#146;m excited to welcome Brendan to our
leadership team. His appointment comes at a time of significant opportunity and growth for CRISPR Therapeutics,&#148; said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. &#147;Brendan&#146;s business and financial expertise
will be important in helping us continue to evolve the Company and realize our mission of transforming the lives of patients with serious diseases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Kulkarni added: &#147;On behalf of the Board of Directors, shareholders, and our employees, I want to thank Mike for his contributions as CFO and for his
dedicated service since joining CRISPR Therapeutics. Mike has been a valuable part of the continued development of the Company, and we wish him all the best in his retirement and look forward to working with him on a smooth transition.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to CRISPR Therapeutics, Mr.&nbsp;Smith was the Chief Financial Officer&nbsp;&amp; Corporate Strategy of Translate Bio, a leading mRNA company that was
recently acquired by Sanofi for $3.2B. Mr.&nbsp;Smith is an accomplished executive with more than two decades of experience within high-growth biopharma environments where he made significant contributions in various operations and strategy
positions. In these positions, Mr.&nbsp;Smith provided strategic financial leadership relating to long-term growth planning focused on operational efficiencies, building manufacturing and supply capabilities, and evaluation of business development
opportunities and commercial planning assessments. Previously, as a Partner at Boston Consulting Group, Mr.&nbsp;Smith led integrated biopharma client engagements that included planning and executing on R&amp;D strategy, operations, business
development and deal diligence. Prior to that, Mr.&nbsp;Smith was VP, Head of Business Operations for Worldwide R&amp;D at Pfizer, where he led financial and headcount planning across discovery and development operations. Prior, in his role as
Executive Director, Head of Business Strategy and Operations for Biologics Pharmaceutical Sciences at Pfizer, Mr.&nbsp;Smith led manufacturing and financial operations for the company&#146;s global biologics process development organization.
Mr.&nbsp;Smith received a B.S. in Biochemistry from Worcester Polytechnic Institute and an M.B.A. from Harvard Business School. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CRISPR
Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range
of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&amp;D operations based in Cambridge, Massachusetts, and business offices in San
Francisco, California and London, United Kingdom. For more information, please visit <U>www.crisprtx.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRISPR THERAPEUTICS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> word mark and design logo are
trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Susan Kim </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-617-307-7503</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>susan.kim@crisprtx.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rachel Eides </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-617-315-4493</FONT></FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>rachel.eides@crisprtx.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>### </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>crsp-20211014.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 10/14/2021 3:01:52 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:crsp="http://www.crisprtx.com/20211014"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.crisprtx.com/20211014"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crsp-20211014_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crsp-20211014_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>crsp-20211014_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 10/14/2021 3:01:52 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>crsp-20211014_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 10/14/2021 3:01:52 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="crsp-20211014.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g212374g1013042856765.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g212374g1013042856765.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H & # 2(  A$! Q$!_\0
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MO9* /&_^&>],_P"A@OO^_*4?\,]Z9_T,%]_WY2O9** /&_\ AGO3/^A@OO\
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MKG_7TG_H KV2O&_V?/\ D#:Y_P!?2?\ H KV2@ HHHH **** "BBB@ HHHH
M*\;_ &@_^0-HG_7T_P#Z :]DKQO]H/\ Y VB?]?3_P#H!H J? _4K71_"7B7
M4;V3R[:VF621O81_SJ>R\3?$WQZ\E_X;CM-)TD,5B:<*2^/=@23] !7'^$[&
MZU#X/>,8K3<72XBE9%'+(H5F'Y#/X5[%\*=7T[4O &EPV4D8DM(1#/""-R..
MI(]^N?>@#*T[7?'UIX7\02>([&WM[BP@9K:]3'[U@,YV\@CISQ]*Y30_$'Q<
MUW0?[;TZ[L+BT&[Y&BC#MMZ\8'IZUZ=XPO[.\\$^(H[:ZAF>"UD258Y Q1MN
M<''0UX7I!\>V'PT;4-&U#&AEI$D@A13*@R0S'*YQGN#Q0![;\.O&,OC/PZ;N
MYMQ!>02&&=5^Z6'<?X5B:OXMUJT^,FF^'H;I%TR>,-)%Y2DDX_O8S3O@P=#C
M\&K%IE[Y]T[F2[63"NKG_9ST]#WK#\0?\G%:-_UQ7^1H BF\8>/O%WBC5;+P
ME-9VEOII(\N54WRX..K \G\!6MXV\4>,/#/P^TR]N)K6VUJ6<1S^5&'3![8.
M1GZ50\9_#PQ:A?>*O!^LBSU"W+27,"2@#<.3@CH?]D\&N:\6>*[KQ?\ "/3K
MR\0+>1:@(9'5<*Y X84 ;5YXE^*WA;3HM=U?^SKW2_D:145<A6_W0".O7FK/
MC+Q]XEDUKPY;>%KJ.W76+972.:)&^=B ,D@XZU&W@#X@^)],L[+6_%%I_8[*
MCF.%/FVX&!@(N?Q-9?Q'TN>P\>>$-+T.9;>XA@2&TEEY"L& !/![^U &PGC;
MQWX-\0:;:^-8[*XL+^3RQ- !N3D D;<=,C@CI1^T'_R!M$_Z^G_] -<O/_:;
M?$S3=/\ B;JCB"U;S+>0(H@D.01R  %)&"<9XP<5TW[0#K)H>A.C!D:Z<AE.
M01L- Q?V?0#HNN C(-TF0?\ <%:^M?!+0K_4'O=,OKS2'D)+I;$%.>N >1],
MX]J\(T3Q;KWAN&:+1]3DLXYF#R!%4[B!C/(/:M3_ (6GXU/_ #,<_P#W[C_^
M)H ]XT/X5Z#H.BZAI]O)=/+J$)AN+IW&\K[#&T=?2MWPMX6L_">@)H]I+-/;
MJS-F?!)W')!P ,5\U_\ "TO&W_0Q7'_?N/\ ^)I/^%I^-L9_X2.?_OW'_P#$
MT"/9=9^">@W^H-?:9>WND3.VXBV8%1ZX!Y'X&MYOA]I\GBK3_$,EY=M>64*Q
M*NY=CX&,GC.?QKY]_P"%H^-\9_X2*X_[]Q__ !-'_"TO&P_YF*XY_P"F<?\
M\30!Z]JGP.T>_P!4GO+?5]1LX[AR\T",&#$G)Y/./KFM[4?AEH5_X5L_#T;7
M%K9VLHE4PL-[-W+$@YS7@1^*?C8=?$=P/^V<?_Q-+_PM+QM_T,5Q_P!^X_\
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M7GD::M#L\J/48_+8NFQ)!M8]2,=#[U)-)KMS)YEPVJS/L*;I/-8[3U7)[>U
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*/3IGJ.*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d212374d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crsp-20211014.xsd" xlink:type="simple"/>
    <context id="duration_2021-10-14_to_2021-10-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001674416</identifier>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2021-10-14_to_2021-10-14"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag contextRef="duration_2021-10-14_to_2021-10-14">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-10-14_to_2021-10-14"
      id="Hidden_dei_EntityCentralIndexKey">0001674416</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-10-14_to_2021-10-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-10-14_to_2021-10-14">2021-10-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-10-14_to_2021-10-14">CRISPR THERAPEUTICS AG</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-10-14_to_2021-10-14">V8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-10-14_to_2021-10-14">001-37923</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-10-14_to_2021-10-14">Baarerstrasse 14</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-10-14_to_2021-10-14">6300</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-10-14_to_2021-10-14">Zug</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="duration_2021-10-14_to_2021-10-14">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="duration_2021-10-14_to_2021-10-14">41 (0)41</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-10-14_to_2021-10-14">561 32 77</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-10-14_to_2021-10-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-10-14_to_2021-10-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-10-14_to_2021-10-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-10-14_to_2021-10-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-10-14_to_2021-10-14">Common Shares, CHF 0.03 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-10-14_to_2021-10-14">CRSP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-10-14_to_2021-10-14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-10-14_to_2021-10-14">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140681851986056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001674416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 14,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CRISPR THERAPEUTICS AG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">V8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Baarerstrasse 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zug<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">41 (0)41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">561 32 77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Shares, CHF 0.03 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRSP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MK)A>R=:[9M[F?"/LF@'(%Q;7DN$ZX_ET,9N3Y?-D/II-OBZGXP49?40 [TO
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #O.4Y3F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M .\Y3E,C/,M*)@0  "\0   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #O.4Y3GZ ;\+$"  #B#   #0
M            @ %H#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .\Y3E.7
MBKL<P    !,"   +              "  40/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( .\Y3E,<.&7J/P$  #P"   /              "  2T0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #O.4Y3)!Z;HJT   #X 0  &@
M        @ &9$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #O.4Y399!YDAD!  #/ P  $P              @ %^$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #($P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d212374d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d212374d8k.htm">d212374d8k.htm</File>
    <File>crsp-20211014.xsd</File>
    <File>crsp-20211014_lab.xml</File>
    <File>crsp-20211014_pre.xml</File>
    <File>d212374dex101.htm</File>
    <File>d212374dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d212374d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d212374d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crsp-20211014_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crsp-20211014_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crsp-20211014.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crsp",
   "nsuri": "http://www.crisprtx.com/20211014",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d212374d8k.htm",
      "contextRef": "duration_2021-10-14_to_2021-10-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d212374d8k.htm",
      "contextRef": "duration_2021-10-14_to_2021-10-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.crisprtx.com//20211014/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-298277-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-298277-xbrl.zip
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M4K:]B[@OXE(36,0VO#X\X%N^1K8U@@P+'<^/%WHZM.J9X&EE"K>M\5K&N4A
M]+QVNZ7G"@]E@G"AZ^L2#RVE]L8S4QU3<PYF( 0D=T5:CKK.+>MY5T)>\[M
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M8"XOD+A8$0YY&FOB$?!*TJ%$Q'-YH0E[0A0-*@06&$'+P">^N!6!BHASJ:R
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M*()0' &^:;5=K,QY-.ZNT&(/?%6\5@';V2I:%S0J-550;Y&;+XUW&+XAG+O
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MEIF\2]1ZD9?I^['P20G)N<?@?U"Q@9WM)W[7Y^*=I$V$C=CTL41GKT5Q9O_
MFM]NM?<..KZX:X%3',7C\A,YU54'.ZH(F6W*;!.AY;$+6Q5.OZ(CXTM%\C<5
M/V+TIQ;_X:$3_Q4E'=<NZ0#)EA^$7JD1SU(M->K.HPH54T@Z<$@U]'1;[\NR
MO*QJ8R]XQ>Z/:= ?.&7X%T[K>>^=74U\W@GX&I=K2O^@W?G[BY.;7Z[/>H]_
M1#]7<K/I&.VQ9Q=M-DKM2V[>^7C V\,]"]_JLTW27'4):_9V6Q)+1WTQXL$
MO18.9&N)M@$6<A+<3Z3A0#@CI6%ABQO"?PDD78J=YUXJ]"*%OMN@Z=6O4M]J
MQ%6O'WEXTEX4@/XBTGRB0+'-ZUZV ^-?-G(62_<J:WA=$BB6_;VH^X=_-+U5
M\9^>+P* QVK[]8"%_<-RW7*8]6VJTM;J\V;:?=+YMGLMRYK+Q%L&R89IL!Z'
M:>(1^SD)/G,=RB=_]\J?QRU]0UHZ+[4JNQK5W]:?!?<-C5P>G6C;8?Z/,.A-
M$Y=7C;[RI_ -9,?!\?\ 4$L#!!0    ( .\Y3E-'GQA4#3X  ,@0 0 1
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M6CA"-3#:'.?,9^#>UFP;],R=Y&75(-EL \/3-&!8^+XYK^"GM,/\N-6F/,^
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M'0M6(W'+L.MH.AG3,_"HQ&H.QD6-7S^-3=R5PB+H2>52C+Q:L,?K-1Q?HL#
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MM?5NU=P6MFQ^<;==>R//C33'B#VY)R@N*8>3^3!,D:Z=&99T(CR=RIZ]\<M
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MU1C&!9:JL58!EF(ZH;YNS35+\9?56$YC58_M_'0R?E#*,!YS%MB=KK/0',S
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M9EU8VZNCO\,O?SW[[<73_P=02P,$%     @ [SE.4[%[;H$J"@  1!P  !$
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ML9IDV8<S9KF,V(3#7:S]L4@>N%&RR49Q<!DT2SKWOXJP<-S=*!*)U=,SG3;
MZ](S[[MEL\)2EEEG545B3\\<V5:O4>C93#"9D@OD#,)-(22F(2=#("U5X9@E
MECJA+-KA!IV+=$\0&H*2I=+:4E*K['=2@#T)W'!DS9 _0-5ZJGV;_4$)SXO+
M[J4)*MA![TA$IR6*0P5(8I[,G1\PO:NY<22_E :9I TTRD((1:P38D[3 4$
MB#1+]%J0B W8BO!T*<G5 S+[03A.Q-+C:N2LH)2P&V5P4?(+ZK6(-)(3<S?)
MC5CB_U_ 2H)T+PO<'3&.FPF!G&5+GA1\AH3-P+*--YN81BP22Y'H;*.I.Y'U
M'JT$8F1C&)2B^TG<@IFPGB0;31)N.RU/M'X@!U:$%N6;-@]DJHLSG:'57DGX
M7T5\!*89,FQ?5GY;%E9 T0&ROZZ4Y9.G&:JG-L@>DO.)KP;K)R)/U9-DAN!(
MQW<75>%TDHR[2'^I>4F05.&O!6"-V&P-?5!Z+ATK_O4F..X^J5ZD5$ UI/,2
MQ K;1"4:#OBJL+%\I1'R$&+G\G!;I=Q"%]-%W"K5JZKU$/.E-%JE/F>!&2@F
M$(Q(/%+!QY3&:4ON,[LJF7:W8J[KM4Q[ H"X T5@6Q!U\]V3@&1&+V4D=DON
M5M)V)-R(I.P_-!BI%BV4RW2CR1FZ*Y<^.PW+;DD7%%W"1%(*SPJ9^)!Q5<QY
MF!>^ I,7198A5B'/^$PF,%F4*B!<SFT:RTJ!=U*M7ML6#"D\* A?*HQSI3(1
M/1]V.M@#-C)B26@FE)K8PT;(:(6" /ITM<UQ70^H%8ES_0KE.7N"8 )_4=+$
MPCA=V48X3$B0$>@%7P@?9\=+W[M@Z=8F5?$+GW#IV*7 9175G0[) >C=)SG;
M2@T=$J%J0/,Q4A$!R;\R-^GBO<GX>=1$I\2=#G<WL ZWW*(<^:)-$F%H$Y5=
M\&(TASZ8YI:ZA,.6.F1-C'-#-)OYCJ>AT=:5I5 OA5F75N\(9G5U:7VSDD5J
MD2BEM^5[4SCVN%!I!EWPC3]0CD0O:'(9/>Z[)XZDOBG9^+<GVD]YN_5;/[[*
M5P8G2IOV89'H&1;.*B.0@N$W9&;:++B2O[F3@GKM&R-(U. _!AK6#28!(02?
MPEB@4\@!ZMSHE**&8ZFK'>EDG8LP5DCN@;*YS OHIQ^(V&W0#2X"O^6:FR55
MF2V*8:QU\J?=Y8=G&M8N9KK(RQI2KSV:+_>,YCL6O'L. _:-M50$JO)"<Q9#
M\^ R=,]\5@;OGTQH]1K!OF R=YS(4$5RCFAZVPYZW'ZD1,KIZ.#1M\Y20YVD
MJQ.TZ9&]+OA$M[(RHNO0*V]$!B[A_B:L,'Z<P:2D%C 1JH%#= K27-Y=!/O*
MNVN*P#$T0[Y(<D82/->)U&7KLUE+'D$A4[N1 ,R]1B-I#=T&\9YO<&#H +G=
MF?! :TU)(Y5&DQN[FJ!5Z/QIPFURU7BL-P#[%AH';1M@S'Y4T$4B7$_A)3>C
M'X0W*A0,Q\%_Q\MMJ801"9_I3<:OO$)XQGB24"G:NM+E:]*4SQ@4Q-=Z[;'\
M^)KU6?(>LA6=K@KW@WYQ10$G<?VU0+D2QA4@]G.Q>/2VH^G-D:Z]@)WKEEXI
M++TGQ;#%S,I(@BE[7?:W^]*[T?P=9?-LQIT]GF+0CQ;"OTSA88Q\R/.R:%=E
M6KONSK4O$WH5\,F06J($X'*,.8!>2>ZVW&@5:=5D]\J-ES\"M$B#[9] 5==R
M255F%JW*$D<8S- R9^W[SFJU"D(C;6;RKP'P;Q_<=X)-!WQP.?@,&2G?1]9K
MS/UM9PCG.A&/14VD3R2%OLI0R%LST/.A-1.P0YSR9,77EM[%M:_';#+X&=KT
MIK$YTKT//7WUT?UIL"^#R^GU>>/H\/"[ZM5:KW\W[8__[UZ65H)XW1]?C/KW
MTT%OTI[<[WDU^N'DNS.VI,D7%&XY T]A1:/S&IEYUC[ I@[-+%0VS4-9[ZG#
M11NYT)3L]1KR*1+TV):S[T):S^N=)_MG=&1#P"XP16D2&_:W3N+&S]LDLC!\
M74J5-%AOL_*U%B6+L<'+ST^H?0.%(3ZG%QM8B,;B]"]*WK-$>%)8E/\?,4#^
MQ0OK?^[AI^'=M.)SC,QNV0RR=ZKT"H%\C@7_/FJ].WK?>G/XOO7^Y/!-^X V
M=![_>'D_[SN60 T>9/J?71UB)$0O_88./+I%^>-/2?22/H^A^2)A?4GC[PLS
M]F_2I%Y[#B8=G;3>OOWX)TQZ24?O.\;A&@C"=3^77E*4]OSBY]6K5[N$VE--
M\71X^1.^=+\]_!U02P$"% ,4    " #O.4Y3HM^OYTH#  !["P  $0
M        @ $     8W)S<"TR,#(Q,3 Q-"YX<V102P$"% ,4    " #O.4Y3
M.[?$YU4&   %1   %0              @ %Y P  8W)S<"TR,#(Q,3 Q-%]L
M86(N>&UL4$L! A0#%     @ [SE.4YC-'".R!   [RH  !4
M ( ! 0H  &-R<W M,C R,3$P,31?<')E+GAM;%!+ 0(4 Q0    ( .\Y3E/7
M.E'JBA@  %6$   .              "  >8.  !D,C$R,S<T9#AK+FAT;5!+
M 0(4 Q0    ( .\Y3E-'GQA4#3X  ,@0 0 1              "  9PG  !D
M,C$R,S<T9&5X,3 Q+FAT;5!+ 0(4 Q0    ( .\Y3E.Q>VZ!*@H  $0<   1
M              "  =AE  !D,C$R,S<T9&5X.3DQ+FAT;5!+!08     !@ &
+ '\!   Q<      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
